BWP
UTHR icon

Baldwin Wealth Partners’s United Therapeutics UTHR Stock Holding History

Baldwin Wealth Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-150
Closed -$53.8K – 979
2024
Q3 		$53.8K Buy
150
+15
+11% +$5.07K ﹤0.01% 536
2024
Q2 		$43K Hold
135
– – ﹤0.01% 371
2024
Q1 		$31K Hold
135
– – ﹤0.01% 437
2023
Q4 		$29.7K Hold
135
– – ﹤0.01% 447
2023
Q3 		$30.5K Hold
135
– – ﹤0.01% 463
2023
Q2 		$29.8K Hold
135
– – ﹤0.01% 485
2023
Q1 		$30.2K Hold
135
– – ﹤0.01% 499
2022
Q4 		$37.5K Buy
+135
New +$34.1K ﹤0.01% 453

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Baldwin Wealth Partners's UTHR Position: Q4 2024 in Review

Baldwin Wealth Partners sold out of United Therapeutics (UTHR) in Q4 2024, closing a stake of 150 shares — an estimated $53.8K sold.

Baldwin Wealth Partners first reported a position in UTHR in Q4 2022 and held it in 8 quarters. The position peaked at $53.8K in Q3 2024. 673 funds tracked by Wall St. Rank hold UTHR as of Q4 2024.

  • Baldwin Wealth Partners reported no remaining United Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Baldwin Wealth Partners sold 150 United Therapeutics shares in Q4 2024, an estimated $53.8K.
  • Baldwin Wealth Partners first reported a position in United Therapeutics in Q4 2022 and held it in 8 quarters.
  • Baldwin Wealth Partners's United Therapeutics position peaked at $53.8K in Q3 2024.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2024.

Based on Baldwin Wealth Partners's 13F filing for Q4 2024, filed 22 Jan 2025.